We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Buys into Myovant’s Oncology Drug Orgovyx for Up To $4.2 Billion
Pfizer Buys into Myovant’s Oncology Drug Orgovyx for Up To $4.2 Billion
Pfizer is expanding further into oncology thanks to a deal with Myovant Sciences, under which the two companies will cooperate on developing and commercializing Myovant’s newly approved prostate cancer drug Orgovyx (relugolix). Myovant will receive up to $4.2 billion, including an upfront payment of $650 million.